Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (281-290 of 520) with videos related to

Pageof 52
Sort By:
Circulation|September 1, 2006
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomasScott D Solomon, Marc A Pfeffer, John J V McMurray, et al.
European Journal of Heart Failure|September 6, 2016
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustmentNathaniel M Hawkins, Pardeep S Jhund, Andrea Pozzi, et al.
European Journal of Heart Failure|February 13, 2018
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumLars H Lund, Brian Claggett, Jiankang Liu, et al.
American Heart Journal|August 25, 2015
Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitusEldrin F Lewis, Brian Claggett, Patrick S Parfrey, et al.
Archives of Internal Medicine|October 12, 2005
Left ventricular assessment in myocardial infarction: the VALIANT registryAdrian F Hernandez, Eric J Velazquez, Scott D Solomon, et al.
Hypertension (Dallas, Tex. : 1979)|November 21, 2007
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarctionJens J Thune, James Signorovitch, Lars Kober, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 9, 2011
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKDAkshay S Desai, Robert Toto, Petr Jarolim, et al.
European Journal of Heart Failure|September 1, 2024
Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trialHenri Lu, Brian L Claggett, Milton Packer, et al.
ESC Heart Failure|January 13, 2021
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trialCorrado De Marco, Brian L Claggett, Simon de Denus, et al.
JACC. Cardiovascular Imaging|April 10, 2009
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic StudyAnil Verma, Alessandra Meris, Hicham Skali, et al.
Pageof 52

Showing results (281-290 of 520) with videos related to

Sort By:
Pageof 52
Circulation|September 1, 2006
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomasScott D Solomon, Marc A Pfeffer, John J V McMurray, et al.
European Journal of Heart Failure|September 6, 2016
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustmentNathaniel M Hawkins, Pardeep S Jhund, Andrea Pozzi, et al.
European Journal of Heart Failure|February 13, 2018
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumLars H Lund, Brian Claggett, Jiankang Liu, et al.
American Heart Journal|August 25, 2015
Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitusEldrin F Lewis, Brian Claggett, Patrick S Parfrey, et al.
Archives of Internal Medicine|October 12, 2005
Left ventricular assessment in myocardial infarction: the VALIANT registryAdrian F Hernandez, Eric J Velazquez, Scott D Solomon, et al.
Hypertension (Dallas, Tex. : 1979)|November 21, 2007
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarctionJens J Thune, James Signorovitch, Lars Kober, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 9, 2011
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKDAkshay S Desai, Robert Toto, Petr Jarolim, et al.
European Journal of Heart Failure|September 1, 2024
Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON-HF trialHenri Lu, Brian L Claggett, Milton Packer, et al.
ESC Heart Failure|January 13, 2021
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trialCorrado De Marco, Brian L Claggett, Simon de Denus, et al.
JACC. Cardiovascular Imaging|April 10, 2009
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic StudyAnil Verma, Alessandra Meris, Hicham Skali, et al.
Pageof 52